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Abstract
Over the past decade, invasive techniques for diagnosing and monitoring cancers are slowly being replaced by noninvasive methods such as liquid biopsy. Liquid biopsies have drastically revolutionized the field of clinical oncology,
offering ease in tumor sampling, continuous monitoring by repeated sampling, devising personalized therapeutic
regimens, and screening for therapeutic resistance. Liquid biopsies consist of isolating tumor-derived entities like
circulating tumor cells, circulating tumor DNA, tumor extracellular vesicles, etc., present in the body fluids of patients
with cancer, followed by an analysis of genomic and proteomic data contained within them. Methods for isolation
and analysis of liquid biopsies have rapidly evolved over the past few years as described in the review, thus providing
greater details about tumor characteristics such as tumor progression, tumor staging, heterogeneity, gene mutations,
and clonal evolution, etc. Liquid biopsies from cancer patients have opened up newer avenues in detection and
continuous monitoring, treatment based on precision medicine, and screening of markers for therapeutic resistance.
Though the technology of liquid biopsies is still evolving, its non-invasive nature promises to open new eras in clinical oncology. The purpose of this review is to provide an overview of the current methodologies involved in liquid
biopsies and their application in isolating tumor markers for detection, prognosis, and monitoring cancer treatment
outcomes.
Keywords: Liquid biopsy, Cancer, Circulating tumor cells, Circulating tumor DNA, Tumor extracellular vesicles, Noninvasive tumor detection, Precision medicine Cancer diagnosis
Introduction
Molecular profiling of tumors obtained from individual patients has in recent years been shown to improve
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the selection of personalized cancer treatment therapies, patient responses, detection of drug resistance,
and monitoring of tumor relapse [1, 2]. The standard
method of profiling tumors initially involves obtaining
resected tumor samples by invasive surgeries. The limitations to such invasive procedures include difficulty in
acquiring tumor samples for both tumor quantity and
quality (Fig. 1). Moreover, acquiring biopsy samples
by invasive methods throughout treatment to monitor tumor response and relapse also poses a major challenge in tumor profiling [3]. Heterogeneity of resected
tumor samples as a whole, also limits the use of invasive
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Fig. 1 Comparison of traditional tissue biopsy and liquid biopsy. The schematic illustrates the advantages that liquid biopsies have gained over
traditional invasive surgical methods over the past decade. Shown here are methods of extracting a test sample which usually includes a small
tissue fragment in case of tissue biopsies and blood in LBs. Analytes that are isolated and monitored in LBs include ctDNA, CTCs, and tumor EVs

methods [4]. Additionally, in the case of metastasis,
where tumors have spread and constantly evolve both
spatially and temporally in response to treatment over
time, multiple biopsies may be required as it is difficult
to obtain a holistic image of a tumor [3]. Considering the
challenges associated with traditional biopsies, recent
oncology research has shifted its focus toward analyzing various biological fluids rather than whole tissues
for tumor-derived components; a technique referred to
as liquid biopsy (LB). Since blood contacts most of the
tumors, LBs mostly involve blood sampling, although
other body fluids like mucosa, pleural effusions, urine,
and cerebrospinal fluid (CSF) are also analyzed [5]. Thus,
LB provides enhanced sensitivity in diagnosis and ease of
repeated sampling throughout treatment in a much more
convenient and non-invasive way [6]. Moreover, studies
have also focused on using LBs in the early detection of
tumors [7].

The technique is associated with both genomic as
well as proteomic assessment of a wide array of tumorderived moieties such as circulating tumor cells (CTCs),
shed by both primary and metastatic tumors, circulating
tumor DNA (ctDNA), tumor derived extracellular vesicles (EVs) that are membrane-bound subcellular moieties composed of nucleic acids/proteins; tumor educated
platelets (TEPs), and circulating cell-free RNA (cfRNA),
composed of small RNAs/miRNAs, etc. Taken together,
these tumor-derived components can provide crucial
longitudinal information and data for more accurate
diagnosis by the pathologists regarding both primary
and metastasized tumors. LBs encompass information
like DNA mutations, copy number alterations (CNAs)
of crucial genes [4], transcriptome/proteome profiling
[8], epigenetic alterations [7], metabolite profiling [9],
etc. (Fig. 2). Recent studies are also beginning to include

Lone et al. Molecular Cancer

(2022) 21:79

Page 3 of 22

Fig. 2 Entities analyzed in liquid biopsies and their application. The various analytes isolated from blood in LBs provide a wide variety of information
regarding tumors. Each analyte has a specific application in tumor diagnosis, monitoring, and treatment as described

bioinformatic tools in deciphering disease signatures
using LBs [10].
This review provides an in-depth analysis of existing
and newer methods of LBs involving isolation of CTCs,
ctDNA, and EVs from the blood of patients with various
types of cancers, along with citing applications of these
extracted entities in detection, prognosis, and treatment
of multiple types of cancers.

Circulating tumor cells in liquid biopsies
Tumor cells were reported in the peripheral blood of
patients as early as the 1860s, and significant improvements have been made ever since in obtaining CTCs from
a heterogeneous population of blood cells [10]. CTCs
are initially released from primary tumors in the tissue,
travel through the circulatory system and account for
the development of metastatic (or secondary) tumors at
distant sites in the body [11]. In terms of numbers, their
percentage in the blood is quite low, with nearly one CTC
found per million leukocytes [12]. As far as morphology

is concerned, studies have shown that CTCs vary in
shape, depending on the stage and/or type of tumor [11].
Moreover, CTCs are known to develop into aggregates
by attaching to cells like fibroblasts, platelets, etc., which
have been reported to spread to more distant sites in the
body relative to their isolated CTC counterparts. Such
cellular aggregates are, thus, protected against oxidative
stress and the surrounding immune system [13, 14].
CTCs have gained immense significance in detecting
tumors, replacing invasive tissue biopsies not only due to
their ease in sampling but also in providing data regarding tumor condition in a ‘real-time’ manner. CTC levels
have been shown to change in a much more dynamic
way, running parallel to the tumor condition with greater
accuracy than usual biomarkers in the blood [15, 16].
CTC counts have also been reported to act as a better
indicator of treatment response, with their reduced levels correlating with better overall survival (OS) in a large
cohort of breast cancer (BC) patients [17]. CTCs, moreover, have shown promising results in the early diagnosis
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Fig. 3 Overview of CTC isolation, detection, characterization and clinical utility. Schematic illustrating various methods of CTC isolation and
detection. CTCs must be filtered out from the rest of the cells in the blood like WBCs, RBCs, etc. (a) Isolation and enrichment methods include
assays based on physical properties (like size, density, etc.) of CTCs, their tendency to bind/not bind antibodies and microfluidic properties that
assist in filtering out CTCs from rest of the cells in the sample like plasma or serum. (b) Detection and characterization of CTCs involve various
techniques that employ primers requiring prior information of gene sequence (left) relative to those are exclusively deep sequencing-based (right).
PARE: Personalized analysis of rearranged ends; TAm-Seq: tagged amplicon deep sequencing; CAPP-Seq: Cancer personalized profiling by deep
sequencing; Safe-SeqS: safe sequencing system; BEAMing: beads, emulsion, amplification & magnetic and draw clinically relevant information
regarding tumors. (c) The section summarizes the application of CTCs in clinical oncology

of several types of cancers like that of the lungs, albeit
in a small group of patients with the chronic obstructive
pulmonary disease [18]. Their diagnostic potential was
confirmed by the presence of lung nodules and histotypic
analysis of resected tissue samples later on. Interestingly,
LBs using CTCs have more recently been reported to differentiate between the benign and malignant states of
pulmonary lesions [19].

Current technologies for isolation of CTCs
from liquid biopsies
Various technologies have been used to selectively
detect viable CTCs to obtain information regarding tumors (Fig. 3 & Table 1). One such example is
the EPISPOT (EPithelialImmunoSPOT) assay that

detects circulating tumor cells up to a single cell, and
has been demonstrated by studies to be successful on a
large number of patients with a wide variety of tumors
such as those of BC, colon cancer (CL), prostate cancer (PCa), and melanomas [20]. The assay involves the
use of membrane-bound antibodies against the epithelial cell adhesion molecule (EpCAM, or CD326) present
on tumor cells and their subsequent culturing/expansion in both in vivo and in vivo conditions. The assay
has prognostic relevance in characterizing the protein
secretome of viable CTCs from breast cancer (BC) in
vivo [21]. A similar positive selection cum enrichment
technology for CTCs obtained from LB samples is the
CellSearch system [15, 22]. The technology uses antibody-labeled magnetic beads to pull down CTCs with
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Table 1 Liquid Biopsy analytes and isolation technologies
LB analyte

Tumor type

Technology
Used

Sensitivity/Detection limit

Basis of detection

Ref

CTCs

PCa

CellSearch system

73% for CTC ≥ 2 or 69% for
CTC ≥ 5 per 7.5 ml

EpCAM

[15, 24]

BC, PCa,CL

EPISPOT/S100-EPISPOT

48%; ≥ 2 CTCs

EpCAM, or CD326

[20, 25]

PCa

AdnaTest

2 CTCs

EpCAM, PSA, and PSMA PCR

[26]

PCa

AdnaTest

––

EpCAM and V7 variant PCR

[27]

BC

CellSearch System

––

ER, BCL-2, EGFR 2, & Ki-67

[28]

CTC-Chip

5–1, 281 CTCs per ml

tumor specific antigens

[29, 30]

CD45

[31]

2 CTCs/mL

CD45& DGC

[32, 33]

EasySep Depletion
RosetteSep

ctDNA

SSA techniques

––

EpCAM

[34]

Celsee systems

94%

Size differences and deformability

[35]

ApoStreamTM

2 CTC/7.5 ml

Surface charge & polarizability

[36]

Melanoma

DEPArrayTM System

––

Melan A+

[37]

BC, PCa, CRC

Droplet digital PCR

MAF detection < 0.1%

––

[38, 39]

BEAMing

MAF detection ~ 0.02%

––

[3, 39–41]

CRC, BC

PARE

ctDNA detection < 0.001%

––

[42, 43]

OVC, BC

TAm-Seq/
eTAm-Seq

MAF detection ~ 2%
MAF detection ~ 0.25%

––
––

[39, 44]

NSCLC

CAPP-Seq

MAF detection ~ 0.02%

––

[39, 45]

BC

cMethDNA

––

––

[46]

HEPC

MCTA-Seq

––

––

[47]

ExoMir™ kit

––

Nanomembrane ultrafiltration

OVA

SEC

––

Exclusion chromatography

[48]

AML

Magneto-immunocapture

Higher purity, Lower yield

––

[49]

PCa

Agglutination

––

Lectin

[50]

PC

ExoChip

––

CD63 based immunochips

[51]

Melanoma, PCa

––

––

CD63 and caveolin-1

[52, 53]

PCa

––

––

prostate-specific transglutaminase

[54, 55]

EVs

CTCs Circulating tumor cells, ctDNA Circulating tumor DNA, EVs Extracellular vesicles, BC Breast cancer, CL Colon cancer, CRC Colorectal cancer, OVC Ovarian cancer,
PCa Prostate cancer, NSCLC Non-small-cell lung cancer, LADC Lung adenocarcinoma, AML Acute myeloid leukemia, HEPC Hepatocellular carcinoma, EPISPOT Epithelial
ImmunoSPOT, MIC assay Metastasis-Initiating-Cells, DGC Density gradient centrifugation, PARE Personalized analysis of rearranged ends, MCTA-Seq Methylated CpG
tandem amplification and sequencing, SEC Size exclusion chromatography, SSA Selective size amplifications, BCL-2 B-cell lymphoma 2, EGFR-2 Epidermal Growth
Factor Receptor 2, ER Estrogen receptor 1, AR Androgen receptor, RB1 Retinoblastoma 1, MED1 Mediator complex subunit 1, GAS6 Growth arrest-specific 6, MAF
Mutant allele fraction

epithelial lineage markers (like EpCAM) (Table 1). The
CellSearch system has been prominent in establishing
a correlation between CTC cell counts and predicting
patient survival in PCa [15]. There are, however, limitations to this assay, as not all CTCs in a heterogeneous population bear EpCAM markers and the fact that
CTCs, once fixated, are not viable for further culturing
and functional assays in vivo [23].
Yet another immunomagnetic-based enrichment assay
of CTCs from LBs is the AdnaTest. In addition to the
EpCAM-labeled ferromagnetic beads used in the CellSearch system, AdnaTest includes a polymerase chain
reaction (PCR) step to detect tumor-specific mRNA transcripts [26]. For example, in the case of CTCs from PCa,
the assay consists of a PCR step using primers against

prostate-specific markers like PSA, PSMA, etc. [26]. The
test was also extended to detect tumor-specific splice
variants of transcripts in CTCs enriched from LB samples. For example, the AdnaTest has been demonstrated
to detect the androgen receptor splice variant-7 (ARV7) transcript overexpressed in PCa, lacking the ligand
domain constitutively expressed as a transcription factor [27]. The ligand-independent AR-V7 variant, thus,
results in a subsequent upregulation of AR modulated
genes [56]. Furthermore, these recent studies have correlated detection of AR-V7+ variant CTCs with increased
aggressiveness, poor prognosis and resistance to several
chemotherapeutic drugs (enzalutamide and abiraterone)
in cancers [27]. The clinical remarks from these studies, that non-AR directed therapies would better treat
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AR-V7 + individuals, were confirmed by subsequent
studies of Onstenk et al. that demonstrated the proficient use of cabazitaxel in PCa [57]. Furthermore, CTCs
isolated by the CellSearch System targeted against markers such as estrogen receptor, B-cell lymphoma 2 (BCL2), Human Epidermal Growth Factor Receptor (EGFR)
2, and Ki67 are crucial in the development of novel
CTC-Endocrine Therapy Index, a parameter predicting
response to endocrine therapy in patients with BC [28].
Apart from using antibody-labeled beads for the positive selection of CTCs, alternative approaches like microfluidic devices have also been used to select CTCs in
various types of cancers [58, 59] (Fig. 3). Devices like the
‘CTC-Chip’, which contains thousands of small antibodylabeled microposts, have been used to capture CTCs
bearing specific tumor antigens from the LB blood sample [29]. Newer designs of ‘CTC-Chips’ have been demonstrated to employ better patterns of microgrooves,
which seem to increase the contact time between antibody-labeled microposts and CTCs, improving cellular
entrapment. CTCs filtered off from LB samples by the
chip are then imaged and analyzed [30, 60].
Moreover, functional assays like the Metastasis-Initiating-Cells (MIC) assay analyze the invasive properties of
CTCs obtained from LB into the surrounding matrix in
vivo, assisting in their further characterization [61]. These
analyses, therefore, aid in providing a detailed picture of
tumor staging/subtypes and in designing novel personalized therapeutic drugs against tumors [62]. In addition
to general nuclear and surface-specific markers targeting
CTCs, counterstain markers that target cells in exclusion
to CTCs such as white blood cells (WBCs), platelets, red
blood cells (RBCs), etc., can also be used to enrich CTCs
from blood samples. The prominent markers selected
for counterstains include CD45/CD66b (granulocytes),
CD235a (RBCs), CD41/CD61 (platelets), CD4/CD8
(lymphocytes), CD11b/CD14 (macrophages) and CD34
(hematopoietic progenitors/endothelial cells) [63–66].
Technologies like the EasySep Depletion Kit (StemCell
Technologies) use CD45-labeled magnetic beads to negatively select WBCs, depleting them from the LB samples [31]. Similar negative depletion technologies have
been developed by others [67, 68]. Other examples, like
the RosetteSep (StemCell Technologies) method, use an
additional density gradient centrifugation step for further CTC enrichment [32]. The limitations of negative
selection methods are that other blood components, like
endothelial cells that are CD45−ve can also crossover,
and there is a greater risk of CTC loss in bulk WBC pulldowns [31].
Although expressed differentially on cancer cells, tumorassociated markers have a pitfall of being lost over time in
CTCs due to cellular changes and dedifferentiation, even
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in aggressive forms of tumors [69]. Apart from differential
expression of antigen markers, several other techniques
have been reported that have enabled proficient identification and isolation of CTCs, such as differences in their
physical properties vis-a-vis WBCs. Separation methods
based on size exclusion have been reported to separate
CTCs (mean diameter—15.6 μm) from WBCs (diameter
range of 7–15 μm), as the former were relatively larger [70].
The limitation was that in many cases CTCs are nearly
the same size as WBCs, resulting in a loss of up to half the
CTCs in techniques relying solely on size exclusion [71].
In addition to this, smaller CTCs were also reported to be
correlated with greater metastases in PCa [72]. These limitations have been overcome by using selective size amplifications techniques of CTCs that artificially increase their
size using microbeads labeled with anti-EpCAM antibodies, improving cell recovery and purity [34]. Differences in
deformability between CTCs and normal blood cells have
also been exploited to isolate CTCs by allowing passage
through microfluidic channels. These studies have revealed
that the relative differences in deformability between
WBCs and CTCs are much more prominent (CTCs being
more deformable than WBCs) than between CTCs themselves, thus enabling proficient detection and isolation of
CTCs [73]. Newer methods have also been developed more
recently (Celsee systems) that use both size differences and
deformability to isolate and analyze CTCs. These systems
use microfluidic devices that house fluidic channels, along
with capture chambers that entrap relatively larger tumor
cells, whereas normal cells like WBCs pass through [35].
Furthermore, since the system entraps unlabelled cells, it
can also be used for downstream analysis of CTCs by various techniques such as immunocytochemistry or in situ
hybridization methods such as ‘FISH’. These microfluidicbased devices (Celsee systems) have indeed shown better
sensitivity in detecting CTCs, as evident by their higher
CTC counts relative to technologies based on cell surface
markers (CellSearch system). The propensity to lose small
CTCs still exists in these systems, though. Similar antibody
independent technologies that are employed to isolate and
recover CTCs from blood include the ApoStreamTMdevice,
which analyzes the differences in surface charge and
polarizability between CTCs and normal blood cells [36].
Subsequent studies have again demonstrated these dielectrophoresis-based systems result in enhanced detection and recovery of CTCs in PCa relative to the surface
marker-based systems (CellSearch system) [74].
Post-enrichment technologies, like the DEPArray™ System, have also been demonstrated to successfully isolate
and recover single CTCs (like Melan A+ melanoma cells)
from LB samples of whole blood [37]. Here next-generation
sequencing (NGS) analysis is carried out directly on CTCs
using technologies such as the Ion Torrent PGM™ system,

Lone et al. Molecular Cancer

(2022) 21:79

composed of the Ion AmpliSeq™ Cancer Hotspot Panel,
which provides enhanced mutational analysis and avoids
the use of error-prone methods like whole genome amplification (WGA), thus improving screening accuracy [37].

Application of liquid biopsy-derived CTCs
in clinical oncology
Mutational profiling of CTCs for tumor-related genes
provides crucial information regarding tumor characterization and predicting the outcome of therapeutic responses. For example, secondary point mutations
in the epidermal growth factor (EGFR) gene, where a
threonine residue replaces methionine (T790M), have
been associated with tumor relapse and confer resistance to otherwise effective therapeutic agents such as
gefitinib and erlotinib in patients with lung adenocarcinoma [75]. Interestingly, such mutations may positively
predict therapeutic responses against newer irreversible
EGFR tyrosine kinase inhibitors [76]. Similar mutational
profiling of CTCs for EGFR-related genes like KRAS
and PIK3CA indicates therapeutic outcomes in colorectal cancer (CRC) [77]. These studies reveal that heterogenic expression and genomic alterations in these genes
across individuals may account for their varied response
rates to treatment in CRC [77]. Thus, the molecular and
genetic profiling of CTCs isolated from patients assists in
detecting ever-evolving changes in the tumor genotype in
a “real-time” manner (otherwise not detectable by conventional tissue biopsy) and in devising newer and more
effective therapeutic responses.
CTCs isolated from LBs can provide valuable data on
epigenetic changes of various tumor-relevant genes in
cancers. Epigenetic alterations, like DNA methylation,
in the promoter regions of tumor/metastasis suppressor
genes, such as SOX17, BRMS1, and CST6 in EpCAM+
CTCs isolated from individuals with BC, are known to
be correlated with enhanced tumor metastasis and poor
prognosis [78]. Similar alterations in the methylation
profiles of genes like VEGF and SFRP2, associated with
angiogenesis, have been observed in CTCs isolated from
PCa and CRC patients, respectively [61, 79]. Moreover,
studies have also revealed CTCs isolated from LBs to
be an efficient diagnostic tool relative to tissue biopsies
in detecting epigenetic changes in cancer-relevant genes
[79]. In addition to prognosis and diagnosis, epigenetic
alterations, such as estrogen receptor 1 methylation, have
been demonstrated to be indicative of treatment resistance to chemotherapeutic regimens like everolimus and
exemestane in BC patients [80].
Similarly, methylation profiles of non-coding RNAs
(ncRNAs) associated with epithelial-to-mesenchymal
transition, such as miR-200, are upregulated in CTCs isolated from PCa patients [81]. Changes in the epigenetic
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signatures of various genes in CTCs, thus, act as biomarkers assisting in prognosis, monitoring tumor response,
and reflecting corresponding changes in cellular mechanisms suggestive of tumor metastasis. It is of interest to
note that epigenetic alterations displayed by CTCs (or
ctDNA, as discussed later in the review), though quite
valuable in cancer prognosis, do not always reflect the
state of primary tumors which constantly evolve [82].
CTCs can also be used in vivo for the generation of
patient-derived tumor models that assist in treatment. It
has been shown that BC xenografts composed of luminal
BC CTCs contain MICs that are shown to induce metastasis of bone, liver, and lungs in mice [83]. The study
revealed a correlation between CTC surface markers like
EPCAM+, CD44+, CD47+and MET+ve, with an increase
in the number of metastatic sites and reduced survival
rates, thus providing data for the development of better
diagnostic tools for the treatment of metastatic BC [83].
Similar studies on LC CTC-derived xenografts have provided better insights into therapeutic drug trials, disease
prognosis, and resistance mechanisms [84]. To overcome
the problem of low numbers of CTCs, studies have also
focused on generating continuous cell lines from CTCs.
For example, the CL cell line CTC-MCC-41 established
from patients has been shown to have a stable phenotype
sharing properties with its primary tumors, thus allowing functional studies and both in vivo and in vitro drug
therapeutic trials to be carried out [85].

Circulating tumor DNA in the liquid biopsies
Early studies by Leon et al. first demonstrated that
patients with pancreatic cancer (PC) had elevated levels
of ctDNA in their sera which seemed to decrease posttherapy [86]. Soon after, studies revealed that it was not
only the levels that were altered in tumors but also their
sequences, with ctDNA samples from plasma of patients
with tumors reporting mutations in oncogenes such as
KRAS [87]. Moreover, studies have established ctDNA
(or chromosomal fragments) to be transferred horizontally via uptake of apoptotic bodies released by tumor
cells, resulting in genetic changes in the host cell, promoting cellular transformation and metastasis [88]. It
must be noted that ctDNA accounts for only 0.1–10% of
the total circulating cell-free DNA (cfDNA), whose normal plasma levels range from 10–100 ng/ml [89]. Physiological states such as inflammation or exercise are also
known to enhance cfDNA levels, which are not always
reflective of underlying malignancy [90]. Moreover,
ctDNA levels in the plasma vary subject to tumor load,
tumor stage, and therapeutic response [91]. In addition
to quantification, clinical application of ctDNA in precision medicine also allows analysis of ctDNA variants in
the plasma. Recent studies have shown ctDNA to differ
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in length from the circulating cfDNA pool, with reports
indicating ctDNA fractions in patients with cancer to be
20–50 base pair, relatively shorter than cfDNA [92].

Current technologies for ctDNA analysis
from liquid biopsies
The relative comparison of data from several sources is
still a major hurdle in ctDNA analysis in clinical usage,
as methods of sample handling, ctDNA isolation, and
analysis have not yet been fully standardized, and a complete analytical consensus is lacking. The observed variations in both the quantity and the quality of ctDNA must
be attributable to biological changes accompanying the
tumor and not to the artifacts generated due to variation
in sample handling. Studies have therefore focused on
analyzing the effects of various ‘preanalytical’ factors like
clotting [93], DNA leakage from WBCs and hematopoietic cells [93], freeze-thawing, DNAse activity of blood
[94], PCR compatibility of reagents [94], the time-lapse
between blood drawing and analysis [93], and temperature [95] in ctDNA analysis. Limitations associated with
isolation and analysis of extremely low levels of ctDNA
have to a large extent been reduced by ever-evolving
technological applications [4, 96].
Two major types of approaches have been considered
for ctDNA analysis: targeted approaches that focus on specific gene rearrangements or gene mutations in particular genomic regions that act as ‘hotspots’ for variation in
a given tumor type, or untargeted approaches that offer a
broader analysis and monitoring of the tumor genome, providing information on nucleotide alterations, copy number
aberrations, chromosomal alterations, etc., independent of
any prior data on molecular alterations (Fig. 3). Targeted
approaches include PCR-based methods such as droplet
digital PCR and BEAMing that have shown remarkable
sensitivity of 1 to 0.001% in detecting somatic point mutations (Fig. 3) [97, 98]. Droplet digital PCR involves partitioning the sample DNA (target and background DNA)
into numerous independent partitions or droplets. The
target sequence is then amplified by end point PCR in
each droplet and relative fractions of positive and negative droplets counted (fluorescent probes) that provide
relative quantification of target samples [3, 98, 99]. Digital
PCR has been shown to detect ctDNA in more than 75%
of patients with advanced CRC, BC, and PC and to a good
extent in patients with localized tumors [38, 100]. BEAMing (beads, emulsions, amplification, and magnetics), on
the other hand, is a modification of emulsion PCR where
several different templates are amplified within a single
tube, each in different compartments (or emulsion droplets) but along with primer bound beads that are recovered
with the help of a magnetic field or centrifugal force [3, 40].
PCR-based assays that detect genomic rearrangements
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explicitly associated with the tumor genome have shown
promising results in sensitivity and specificity using
ctDNA. Assays such as personalized analysis of rearranged
ends (PARE), which uses primers flanking the breakpoint
region, have been shown to successfully detect mutant
ctDNA (rearranged sequences) at levels as low as 0.001%
in plasma samples of patients with CRC and BC [42, 43].
PARE analysis of ctDNA thus assists in monitoring disease
burden and the development of tumor-specific biomarkers in patients with solid tumors [43]. Numerous NGSbased methods have recently been developed that offer a
relatively broader screening of the genomic regions, along
with better resolutions in detecting mutations in ctDNA
samples. Assays such as tagged-amplicon deep sequencing (TAm-Seq), developed by Forshew et al., can detect
ctDNA mutations in plasma with very low allelic frequencies (~ 2%) and with high sensitivity (> 97%) [44]. Various
sequence-specific primers first amplify multiple regions of
the targeted area in the genome to allow the representation
of various alleles in the template material, narrowing down
the pool of amplified products. These diverse products are
again amplified for enrichment, tagged with adaptors, and
sequenced [44]. These studies have identified mutations
in the tumor suppressor p53 and EGFR regions in plasma
of patients with ovarian cancer (OVAC), otherwise not
detectable by invasive solid biopsies [44]. Moreover, TAmSeq has also assisted in the longitudinal screening of tumor
mutations over several months in plasma of patients with
BC. Similar deep sequencing methods like CAPP-Seq have
been developed by Newman et al. that allowed the detection of ctDNA mutant fractions as low as 0.02% with high
specificity (~ 95%) in patients with non-small-cell lung cancer (NSCLC) [45]. ctDNA quantified by CAPP-Seq analysis was shown to be better in correlating to tumor burden,
detecting residual disease and accessing an early tumor
response than traditional radiographic methods [45].
Tagged complementary oligonucleotide probes that can be
recovered are used to target specific regions of DNA.
In contrast to the targeted approaches discussed above
that focus on primer-specified regions, untargeted methods are relatively more comprehensive about analyzing the
tumor genome. In this context, methods such as shotgun
massively parallel sequencing of ctDNA from plasma have
been shown to provide whole-genome profiling for copy
number alterations (CNA) and mutations in patients with
hepatocellular carcinoma (HEPC), BC, and OVAC [101].
Similar whole-genome profiling of plasma ctDNA using
high-throughput IlluminasMiSeq has been shown to reveal
various CNAs (androgen receptor amplification) and
chromosomal rearrangements (TMPRSS2-ERG fusion; 8p
loss/8q gain) in patients with castration-resistant and castration-sensitive PCa [46]. Whole-genome analysis using
massively parallel sequencing of plasma ctDNA has also
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enabled the detection of similar alterations in patients with
CRC and BC [102].

Application of liquid biopsy-derived ctDNA
in clinical oncology
Studies have revealed that ctDNA provides a much more
holistic view of tumor characteristics and progression
emanating from primary and metastasized tumor foci
[103, 104] (Table 2). Moreover, mutations undetected
by conventional tissue sampling have been screened
using ctDNAs from LBs [105]. Genome sequencing of
ctDNA has also assisted in detecting tumor-specific copy
number alterations of genes in PCa and reveals a constantly changing nature of cancer cell genomes where
gene amplifications play crucial roles in cancer progression [106]. ctDNA profiling has also enabled tracking of
clonal variations in patients with CRC, assisting in realtime monitoring of tumor progression and therapeutic
resistance against EGFR blockade [107]. Similarly, clonal
profiling of tumor cells using ctDNA has also been studied in PCa where androgen receptor mutations have
been screened that emerge against chemotherapeutic
regimens like abiraterone or prednisolone [108]. ctDNA
profiles of clones in these studies reveal both spatial and
temporal tumor heterogeneity arising due to differences
in resistance mechanisms at different tumor sites.
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Moreover, ctDNA genotyping is known to assist in
determining tumor subtypes in patients with B cell lymphoma, thus assisting in predicting clinical outcomes
and personalized treatment [116]. Relative to ctDNA, a
higher number of CTCs or multiple solid tumor biopsies would be required to access similar outcomes, thus
highlighting the proficiency of ctDNA biopsies. Moreover, unlike CTCs, ctDNAs are known to act as biomarkers indicative of tumor volume, as revealed by studies in
OVAC and lung cancer (LC) [117, 118]. The prognostic
significance of ctDNA in cancer progression and its therapeutic response has been revealed in several types of
cancers such as OVAC [117], LC [118], and CRC [119],
where its presence correlates with relatively poor clinical outcomes and tumor relapse. In addition to prognosis, monitoring ctDNA profiles in patients with BC and
CRC has also enabled the detection of residual disease
post-therapy and the risk of relapse, thus allowing therapy modification and avoiding overtreatment [120, 121].
Plasma-Seq analysis of ctDNAs reveals wide variety of
mutations or aberrations that act as predictive resistance markers against therapies in various forms of cancer. For instance, KRAS-, NRAS, and BRAF-associated
mutations in plasma ctDNA of metastatic CRC patients
drive primary resistance five to six months post-antiEGFR regimens like panitumumab and cetuximab [122,

Table 2 Clinical applications of LB in various cancers
LB entity
EVs

Cancer

ctDNA

Diagnosis provided

Ref

PCa

glypican-1 (GPC1), KRAS mutation

[109]

PCa

miRNAs, CD44v6, Tspan8, EpCAM and CD104

[110]

miR-23b-3p, miR-10b-5p and miR-21-5p

Noninvasive biomarker

[111]

miR-125b-5p

Predicting improved T-cell activity

[112]

NSCLC

miR-146a-5p

Predicting chemosensitivity

[113]

melanoma

miR-211-5p

Predicting resistance to vemurafenib

[114]

melanoma

PD-1 and CD28

Predicting resistance to ipilimumab

[115]

LADC

EGFR mutation

Predicting gefitinib and erlotinib

[76]

CRC

KRAS, PIK3CAmutation

Predicting therapeutic response

[77]

BC

Promoter methylation of SOX17, BRMS1and CST6

Poor prognosis

PCa and CRC

Promoter methylation of VEGF and SFRP2

Predicts angiogenesis

BC

ER 1 methylation

Predicts everolimus and exemestane resistance

[59

BC

EPCAM+, CD44+, CD47+& MET+ expression

Predicts metastasis

[83]

CRC

Genomic profiling

Tracking clonal variations and therapeutic response

[107]

PCa

AR mutations

Predicting abiraterone or prednisolone response

[108]

B cell lymphoma

DNA profiling

Determine tumor subtypes

[116]

OVC, CRC

DNA profiling

Poor clinical outcome

[117–119]

BC, CRC

DNA profiling

Residual disease and relapse

[120, 121]

CRC

KRAS, NRAS, and BRAF mutations

Predicting panitumumab and cetuximab response

[122, 123]

Solid tumors

mutations in PIK3CA, RB1, MED1, GAS6 and EGFR

Predict response to paclitaxel, cisplatin, tamoxifen,
lapatinib and gefitinib

[124]

NSCLC

CTCs

Analysis

[61, 79]

CTCs Circulating tumor cells, ctDNA circulating tumor DNA, EVs Extracellular vesicles, BC Breast cancer, CL Colon cancer, CRC Colorectal cancer, OVC Ovarian cancer, PCa
Prostate cancers, NSCLC Non-small-cell lung cancer, LADC Lung adenocarcinoma, AML Acute myeloid leukaemia
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123]. Similarly, mutations in PIK3CA, retinoblastoma 1,
mediator complex subunit 1, growth arrest-specific 6 and
EGFR confer resistance against drugs like paclitaxel, cisplatin, tamoxifen, lapatinib, and gefitinibin in advanced
cancers [124]. Interestingly, even though resistance
mechanisms that develop over time have different origins
genetically, they seem to converge at crucial signaling
foci. Thus, there are numerous applications of ctDNAs in
diagnosis, prognosis, therapy and drug resistance associated with precision oncology.
Apart from mutations, epigenetic modifications such
as methylation patterns of tumor-derived ctDNA have
been described as biomarkers for various cancers [7,
125]. Similar to screening ctDNA mutations, methods
for detecting ctDNA methylation are classified into two
types: localized site-specific targeting of selected regions
of the genome and a holistic genome-wide approach [96].
Various PCR-based methods require prior knowledge
about the targeted region, such as methylation-specific
PCR (MSP) [126], quantitative multiplexed MSP [127],
and methylation on beads [128, 129], which are known
to assist in detecting methylated DNA sequences. Fluorescence-based real-time modifications to conventional
MSPs have also been shown to facilitate the quantitative
detection of methylation patterns [130]. Assays such as
cMethDNA, a modified version of QM-MSP developed
by Fackler et al., are quite proficient in detecting latestage BCs and monitoring tumor progression and treatment response, as well as disease recurrence [46]. The
assay provides enhanced methylation signals of novel
biomarkers in the sera of BC patients and better sensitivity and reproducibility than conventional QM-MSPs
[46]. Methylation levels were shown to correlate with
treatment response and act as a connecting link between
ctDNA and its parent tissue of origin [46].
Interestingly, these studies found epigenetic signatures
to be retained in the sera of patients several years postdiagnosis of disease. Genome-wide approaches such
as Shotgun massively parallel bisulfite sequencing have
been shown to detect ctDNA methylations with better sensitivity and specificity [7]. Similar genome-wide
approaches such as methylated CpG tandem amplification and sequencing have been described to detect
numerous hypermethylated CpG islands in ctDNA samples as low as 7.5 pg in plasma of patients with HEPC
[47].

Extracellular vesicles from tumor liquid biopsies
Yet another candidate for LBs are extracellular vesicles
(EVs), small 30–100 nm, membrane-bound, saucershaped vesicles secreted by cells and found in various
body fluids such as plasma, urine, cerebrospinal fluid
(CSF), saliva, etc. [131, 132]. Formerly regarded as
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cellular waste products assisting in removing undegraded
endosomal or lysosomal components, EVs have now
been established to play crucial roles in various forms of
cell-to-cell communication [125]. EVs cargo comprised
of diverse biomolecules like DNA, RNA, protein, etc.,
has been established to play crucial roles in intercellular
communication [53, 133–135] (Fig. 4). Most importantly,
tumor-derived EVs have gained immense attention as
studies have described their roles in promoting tumor
growth, epithelial to mesenchymal transition, metastasis, immunosuppression, angiogenesis, etc. [53, 132–
134, 136, 137]. Since tumors have been shown to shed
EVs profusely, their numbers in the plasma of patients
with tumors reach extraordinary levels [134]. As tumorderived EVs contain crucial cargo such as tumor-derived
DNA, mRNA, ncRNAs, proteins, etc. [138] (Fig. 4), their
analysis offers significant insights into tumor monitoring,
prognosis, and therapeutic response.

Current methodologies for the isolation of tumor
extracellular vesicles from liquid biopsies
Several techniques have been described that effectively
isolate EVs from varied cellular debris, exploiting various
unique physical and biochemical properties that assist in
EVs isolation. Preparative ultracentrifugation is known
to be one of the most common EVs isolation methods, accounting for nearly half of all the EVs isolation
methods currently employed [139, 140]. The technique
exploits differences in particulate density, shape, and
size. Variations that prevent EVs loss and contamination
and improve EVs purity, like differential, isopycnic, and
moving zone ultracentrifugation, have been described
by various studies [50, 141, 142]. Other size-based EVs
isolation methods include ultrafiltration, which employs
membrane filters with predefined molecular weight cutoffs [143]. Although ultrafiltration-based isolation methods dispense with the use of specialized equipment like
centrifuges, the vesicles are vulnerable to breakage or
deformation due to force used, thus, affecting downstream analysis [144]. In this context, nanomembrane
ultrafiltration concentrators have been shown to successfully isolate urinary EVs from as little as 500 µl of sample
and assist in diagnosing renal complications [145]. Commercial kits like ExoMir™ (Bio Scientific) employ syringe
filters to capture EVs from cell-free fluids like sera, CSF,
and cell culture media. RNA extraction reagents are then
used to lyse and release exosomal contents, further processed for qRT-PCR analysis. Variations such as sequential filtration that use electron microscopy and mass
spectrometry for downstream analysis allow EVsisolation
with better purity and integrity [146]. Similar size-based
EVs isolation methods include size exclusion chromatography, where EVs are separated from the rest of the
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Fig. 4 Extracellular vesicle biogenesis and cargo. (a) The schematic illustrates the synthesis of EVs (via endosomal sorting complex required for
transport (ESCRT) dependent or independent pathway), inside the cell that begins by inward budding of the plasma membrane. Early endosomes
formed to take up cytoplasmic cargo that includes biomolecules like DNA, RNA, and proteins that play a role in cell-to-cell communication.
Multivesicular bodies, thus, formed containing a wide variety of cellular cargo, soon merge with plasma membrane releasing EVs. Cell-specific
surface antigens are known to be tagged along in certain cases while EVs emerge from a cell. (b) The figure depicts the wide array of biomolecular
cargo (both internalized and surface bearing) that EVs carry and exploited as markers in the characterization of tumors. Tumor derived EVs bearing
numerous markers (as depicted) provide efficient noninvasive ways of LBs that offer real-time monitoring of tumor progression and treatment

components in the sample by being excluded from the
pores in the stationary phase and eluted earlier than the
rest of the fractions [147]. For example, EVs secreted by
mesenchymal stem cells in response to myocardial infarction have been isolated by such size-exclusion methods
[148]. Similar size exclusion fractionation methods have
been utilized for isolating tumor-derived EVs capable of
T-cell suppression from ascites of OVAC patients, which
are then confirmed for biomarkers by Western blots [48].
Moreover, studies have also shown that size exclusion
chromatography, in combination with ultracentrifugation, improves urinary EVs yield and assists in detecting
prognostic biomarkers capable of predicting nephrotic
disease outcomes [149]. Newer size-based EVs separation methods include techniques such as flow field-flow
fractionation, involved in isolating EVs from neural stem
cells [150], and hydrostatic filtration dialysis, effective in
separating and enriching urinary microvesicles to form
relatively larger sample volumes [151]. In addition to sizebased isolation methods, immunoaffinity-based assays

such as ELISA have been reported to isolate and analyze
EVs from body fluids such as plasma, urine, CSF, etc.
These methods exploit the presence of membrane-bound
surface biomarkers that are either specifically expressed
or overexpressed on EVs [139]. Moreover, RNA extracted
from EVs isolated by immunoaffinity-based assays displayed better yield than conventional size-based methods
like ultracentrifugation, capable of extracting exosomal
RNA from as small as 100 μl of sample [139]. Variations
of these methods like the magneto-immunocapture technique that use antibody-coated magnetic particles have
been demonstrated to display yields 10–15 times better than UC [139]. Tetraspanins, such as CD63, highly
expressed on EVs membranes, are known to be exploited
for selective enrichment of EVs from complex sample
mixtures using these techniques (ThermoFisher). Moreover, CD34 + blast-derived EVs captured by similar magneto-immunocapture techniques have been predicted to
act as biomarkers and to be useful in monitoring disease
progression and therapeutic response in acute myeloid
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leukemia [49]. Interestingly, EVs isolated by these methods were shown to be biologically active and capable of
mediating immune suppression. Various studies have
also highlighted variants of magneto-immunocapturebased techniques that offer better capture efficiency and
sensitivity in isolating tumor EVs [152–155]. Precipitation methods that use polymers, like polyethylene glycol,
have been successful in isolating EVs from biological fluids [156]. Commercial isolation kits based on precipitation of EVs include ExoQuick PLUS (System Biosciences)
that are capable of precipitating EVs from serum, plasma,
etc. in a relatively shorter time frame and with reduced
carryover contaminants. EVs so isolated are then analyzed for their protein content by Western blots and for
RNA by qRT-PCR [157, 158]. EVs isolation kits (ThermoFisher, CUSABIO, iZON, qEVSingle, 101Bio) have
also been developed that cater to a wide range of samples
like urine, saliva, CSF, ascetic fluid, and amniotic fluid.
Pre- and post-isolation steps for EVs purification are also
included that get rid of non-EVs contaminants like lipoproteins and polymeric materials, respectively [139]. In
addition to polymers, lectins with a high binding affinity
to oligosaccharide residues on EVs membranes have also
been reported to be quite successful in isolating urinary
EVs [159]. miRNA profiles of EVs precipitated by such
lectin-based agglutination methods have been suggested
to act as crucial biomarkers in diagnosing PCa [50]. Furthermore, microfluidics-based enrichment methods such
as those developed by Wang et al. use ciliated micropillars that exclusively entrap EVs with the exclusion of
other extracellular vesicles, proteins, and debris [160].
Likewise, commercially available microfluidic devices
such as ExoChip, developed by Kanwar et al., successfully
isolate EVs from sera of patients with PCs for miRNA
analysis [51]. These devices capture EVs using a CD63
antibody-coated immunochip, followed by membranespecific fluorescent staining. Exosomal cargo is analyzed
by either Western blot (for proteins) or RT-PCR (RNA).
Similar immunochip-based assays employing antibodylabeled magnetic beads use plasma samples as low as
30 μl with an assay time < 100 min for EVs enrichment
and analysis [161]. Despite the rapid advances made in
EVs isolation and enrichment as described above, the
technologies are still limited in various clinical applications. Issues such as pretreatment of samples, isolation
efficiency, standardization, EVs heterogeneity and more
importantly, yield of exosomal cargo pose some major
challenges to researchers working in this area. Nevertheless, the significance of EVs in clinical applications such
as tumor diagnosis, monitoring and treatment cannot be
underestimated given their huge significance as a minimally invasive technique in these areas, as evidenced by
various sources described below.
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Applications of tumor derived extracellular
vesicles from liquid biopsies in clinical oncology
Post enrichment and purification, EVs analyzed for their
protein or nucleic acid cargo are efficacious as diagnostic and prognostic markers in a wide variety of cancers.
EVs expressing biomarkers such as CD63 and caveolin-1
are known to act as potential indicators of melanoma
[52]; those enriched with migration inhibitory factor
act as predictive markers of liver metastasis in patients
with PC [53]; and those tumor-derived EVs with markers like prostate-specific transglutaminase and stem cell
antigen are indicative of tumor burden in patients with
PCa [54, 55]. Recent studies have highlighted the role
of tumor-derived EVs in diagnosing early-stage PCs.
Tumor-derived EVs in these studies were enriched with
biomarkers like glypican-1, a cell surface proteoglycan,
along with harboring KRAS mutations [109]. Apart from
membrane-bound markers, exosomal cargo like DNA
and RNA are also known to provide crucial information
for the diagnosis and therapeutic response of patients
in various types of cancers. Upregulated miRNA cargos
of miR-1246, miR-4644, miR-3976, and miR-4306 were
reported to act as highly sensitive and minimally invasive
biomarkers in patients with PC [110, 162]. These studies indicated a similar diagnostic potential for exosomal
proteins like CD44v6, Tspan8, EpCAM and CD104. EVs
enriched with miRNAs such as miR-23b-3p, miR-10b-5p
and miR-21-5p in plasma of patients have been reported
to act as significant non-invasive biomarkers for NSCLC
[111]. LB profiles of exosomal miRNAs also assist in
determining the efficacy of treatment against cancers. In
post-treatment plasma EVs, downregulation of immunosuppressor miRNA, like miR-125b-5p, has been correlated with improved T-cell activity and better response
to immunotherapy [112]. A similar correlation between
exosomal miRNAs and the efficacy of chemotherapeutic drugs has been described in the case of cisplatin used
against NSCLC, where elevated levels of exosomal miR146a-5p were shown to result in increased chemosensitivity of NSCLC to the chemotherapeutic drug [113].
Conversely, miR-146a-5p expression levels were shown
to drop in both NSCLC cell lines and EVs in cisplatin
resistance. Furthermore, upregulated miRNA signatures
of miR-211-5p in melanoma and melanoma-derived
vesicular secretome have been suggested as indicative of
therapeutic resistance developed against BRAF inhibitors
such as vemurafenib, used in treating metastatic melanomas [114]. Corroborating with this, these studies also
demonstrated an inverse correlation between elevated
miR-211-5p levels and reduced sensitivity to BRAF inhibitors in vivo. Exosomal cargo such as DNA also assists in
providing firsthand information on tumors. Mutations
in exosomal DNA at regions harboring tumor-relevant
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genes like KRAS and p53 have been reported to be indicative of PCs [163]. In addition to tumor-derived EVs,
studies have suggested that even serum EVs derived from
immune cells act as biomarkers that assist in predicting a clinical response against chemotherapeutic drugs.
Elevated levels of surface markers PD-1 and CD28 on
T-/dendritic cell-derived EVs in melanoma patients have
been correlated with improved clinical response to chemotherapeutic drugs like ipilimumab [115]. More recently,
studies have described small extracellular vesicles (sEVs)
derived from serum to have potential roles in monitoring
tumors of the central nervous system [132].
Apart from miRNAs, other non-coding RNAs like
lncRNAs and circRNAs present in tumor-derived EVs
have also been shown to play promising roles in the diagnosis and monitoring of tumors. For instance, circRNAs
like circ_0044516 have been observed to be upregulated
in PCa derived blood exosomes [164, 165]. Silencing the
expression of circ_0044516 in PCa cells corroborated
with a reduction in growth and metastasis of cancer
cells. Similar roles of non-coding RNAs such as exosomal lncRNAs have been described in PCa [166]. Exosomal lncRNA H19 is known to be upregulated in serum
in cases of bladder cancer, thus, having a potential role as
a prominent diagnostic marker [167]. Similarly, elevated
levels of lncRNAs PCA3 and BCAR4 have been reported
in the sera of patients with CRC [168]. Serum exosomal
lncRNAs ENSG00000258332.1, LINC00635 and HEIH,
on the other hand, have potential diagnostic roles in LB
for hepatocellular carcinoma [169, 170]. In addition to
diagnosis, exosomal lncRNAs also find application in
tumor prognosis, such as lncRNA MALAT1 in epithelial
ovarian cancer (EOVAC) and lncRNA MALAT1, PCAT-1
in BC [171, 172]. Furthermore, exosomal lncRNAs also
find crucial application in monitoring drug resistance
of tumors indicating their potential clinical use in cancer therapy. For example, tumor derived lncRNA H19
displays positive correlation with gefitinib resistance in
patients with non-NSCLC [173]; lncRNA PART1 with
similar geftinib resistance in esophageal squamous cell
carcinoma (ESCC) [174]; lncRNA ARSR with sunitinib
resistance in advanced renal cell carcinoma (RCC) [175];
lncRNA UCA1 expression with cetuximab-resistant CRC
cells [176]. Exosomal lncRNA mediated LB, therefore,
offers tremendous application in real-time monitoring of
tumor diagnosis, progression, and recurrence in a wide
variety of tumors.

Non-blood candidates in liquid biopsies
In addition to circulatory fluids like plasma or serum
discussed above, various other body fluids like saliva,
urine, etc. have also been shown by numerous studies
to have significant application in liquid biopsy. Saliva,

Page 13 of 22

for instance, offers practical advantages with regard to
ease of access, non-invasiveness, and cost effectiveness
in sampling, even more so than plasma or serum [177].
Salivary molecular diagnostics have evolved rapidly over
the past decade with great potential in cancer detection,
monitoring, and development of point-of-care medicine
[178]. Novel electrochemical sensor-based technologies
like an electric field-induced release and measurement
(EFIRM) developed by the Wong lab have been shown
to detect EGFR mutations (tyrosine kinase domain) from
bodily fluids like saliva in patients with non-small cell
lung carcinoma (NSCLC) [179]. Similar EFIRM based
technologies have been used in developing salivary biomarkers (like Foxp1 and Gng2) for the detection of pancreatic cancer [180]. Non-genome-based markers have
also been shown to find application in liquid biopsies
using saliva. Spectroscopic analysis of salivary metabolites have revealed increased levels of porphyrin to be
indicative of oral squamous cell carcinoma (OSCC) [181].
Similarly, changes in the oral microbiome have also been
linked by recent studies with the occurrence of OSCC
[182].
The completely non-invasive nature of urine sampling,
on the other hand, relative to tissue or even blood, makes
it a quite useful candidate in LBs, particularly in cases
where repeated sampling is required to monitor tumor
progression and therapeutic outcomes [183]. Moreover, increasing studies have been directed towards the
use of urine in LB due to the presence of a large number of clinically relevant cell-free molecular constituents
like proteins, circulating DNA/RNA, and EVs that can
be harnessed to monitor tumor oncology. Studies have
described urine LBs to be quite useful in detecting cancers of both urological [184] as well as non-urological
sources [185] with more or less comparable sensitivities
relative to blood LBs [186]. Since most of the biomolecules secreted by cancers of urological origin will most
probably be excreted directly into the urinary tract, urine
LBs therefore, offer easy and continuous monitoring of
these tumors [187]. Some of the already established urinary biomarkers for prostate and bladder cancer include
Nuclear Matrix Protein 22 (NMP22), TMPRSS2:ERG
fusion gene expression, and Prostate Cancer gene 3
(PCA3) [188] [189]. Urinary lncRNAs, like FR0348383,
UCA1, and MALAT1, have been described as biomarkers in PCa even better than similar prostate-specific antigens derived from serum [190–192]. Cell-free nucleic
acids like the IQGAP3 and UBE2C present in the urine
have been reported recently to act as diagnostic markers
for bladder cancer [193]. Non-coding RNAs like piRNA
(piR-823), involved in the silencing of transposons, are
known to be altered in both serum and urine samples and
have been suggested to show promising diagnostic utility
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in patients with RCC [194]. Moreover, circular RNAs like
PRMT5, known to induce epithelial-mesenchymal transition by sponging miRNAs, have been suggested to play
crucial role in promoting urothelial carcinoma of the
bladder and, thus, positively correlated with advanced
clinical stage and reduced survival in patients with
urothelial carcinoma [195]. Ongoing clinical trials like
NCT04432909 (ClinicalTrials.gov) are underway to further examine urine as a source of LB for urothelial carcinoma. Non-urological cancers like those of lungs, gastric
system, colorectal, breast, etc. have also been shown to
be diagnosed and monitored with the help of urine LBs.
Urinary LBs (like plasma LBs) have been quite successful
in detecting epigenetic changes like DNA methylation at
discrete gene loci associated with NSCLC [196]. Moreover, sensitivities of tissue and urine LBs were found to
be comparable (~ 75%) in detecting EGFR mutations
in NSCLC. These and subsequent studies also reported
urine LBs to be modest indicators of chemotherapeutic
response of tumors against given drugs like Rociletinib
and Osimertinib [197, 198]. Recent studies on detection of HCC-associated DNA markers (TP53 249 T;
RASSF1A and GSTP1 methylations) using urinary LBs
have also assisted in monitoring tumor recurrence [199].

Emerging analytes for liquid biopsies
Tumors have been described as altering platelet behavior
in a process termed as tumor-mediated platelet education
[13, 200]. Novel biomarkers associated with such TEPs
have more recently emerged as promising analytes assisting in the non-invasive detection of cancers [201, 202].
RNA-Seq analyses of platelet-derived RNA were reported
to detect both early- and late-stage NSCLC with an accuracy of nearly 80 percent [201]. Furthermore, as tumor
development is associated with various systemic changes
that lead to metabolic alterations, circulating metabolite
levels in the plasma of patients can be exploited as cancer
biomarkers. Elevated levels of metabolites, like branchedchain amino acids, have been correlated with the early
development of human pancreatic adenocarcinoma [9,
203]. Studies have attributed this to reduced utilization of
these circulating metabolites in patients with PCs [203].
In contrast, cancers such as NSCLC that actively utilize
these metabolites are associated with reduced levels of
branched-chain amino acids. Altered metabolite levels
attributed to their differential utilization by tumors might
thus play a crucial role in the early detection of various
forms of tissue-specific cancers [204].
Moreover, like methylation patterns (discussed before),
nucleosome positioning of cfDNA has also been recently
described to differ between various cells and offer valuable information regarding target genes. Studies have
developed genome-wide maps of nucleosome occupancy
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on cfDNA by deep sequencing cfDNA samples from
blood plasma [205]. Nucleosome occupancy/ ‘footprints’
of cfDNAs may be correlated with the expression of
various target genes such as cancer drivers and providing critical information of its tissue of origin [205, 206].
More recently, studies have shown a positive correlation
between a decrease in nuclear cfDNA levels and a transition to longer fragments, and an improved chemotherapeutic response in patients with CRC [207]. Conversely,
increased and shorter nuclear cfDNA content correlated with tumor recurrence [207]. cfDNA analysis, thus,
offers promising breakthroughs in non-invasive liquid
biopsy technologies [100]. Circulating cell-free miRNAs
associated with EVs, apoptotic bodies, lipoproteins or
AGOs (miRISC constituents) are known to be quite stable in a wide variety of body fluids like plasma or serum
[208]. Current studies have increasingly focused on using
miRNA signatures of body fluids as diagnostic tools in
cancer detection. ‘miR-Test’ developed by Montani et al.
analyzes serum miRNA signatures and is quite successful
in the screening of early LCs, albeit in high-risk individuals relative to traditional and expensive methods such as
computed tomography [209]. Similar clinical trials have
suggested the significance of plasma miRNA signatures
in improving the diagnostic and prognostic evaluation
efficacy of LC patients [210]. Therefore, the evaluation
of miRNA signatures in body fluids is an emerging area
of liquid biopsies that might have huge applications in
diagnosing a wide variety of cancers. The evolving list of
analytes that can be exploited in liquid biopsies provide
novel biomarkers that can find immense application in
diagnosis, prognosis, and devising therapeutic regimens
for a wide variety of cancers.

Limitations of liquid biopsies
Recent developments in non-invasive diagnostic and
monitoring tools such as LBs have gained widespread
attention in cancer treatment. However, LBs are not yet
considered a standard tool for confirming and diagnosing different diseases, including cancer, and are primarily
used as a complementary test to tissue biopsy. The major
limitation of LB is the lack of sensitivity and precision to
identify various tumor types compared to tissue biopsy.
Moreover, it is also unclear whether LB provides a representative sampling of all genomic clones within an individual tumor or a specific sub-region of the tumor. It is
pertinent to mention that diverse features of clonal evolution of tumors such as development of drug resistance,
changes in genome, gene expression, epigenetics have
been to a great extent successfully addressed by methods
such as Single-Cell analysis of cancer cells [211–213]. In
addition, the number of CTCs, ctDNA, RNA, progenitor and mature endothelial cells, and tumor-educated

Lone et al. Molecular Cancer

(2022) 21:79

platelets are relatively rare compared to other hematological components in the blood, which makes the detection
ability of LBs challenging [214].
Moreover, a cost-effective pre-profiling strategy is
required for pre-selecting the patients due to the low
frequency of target mutations (in the case of CTCs and
ctDNA) found in a cohort of patients[215]. Furthermore, some of the biomarkers identified through LB are
“fragile” and are difficult to capture. In addition, highly
specific and sensitive methods are required to isolate plasma, and there is a lack of standardized methods or protocols for isolation and interpretation [216].
Another limitation observed with LBs is the occurrence
of false-positive and false-negative results, which can
interfere in correctly evaluating the efficacy of pharmacological treatment [217]. Moreover, the release of biological materials (such as urine and blood) used for LBs
can be influenced by microenvironmental factors [217].
The three typical detection targets of LB are CTCs,
ctDNA, and EVs, of which EVs are challenging to go
from bench to bedside because of the lack of effective
enrichment technologies and precise analysis methods
[218]. Higher morphological heterogeneity and count
of CTCs in different cancers and patients poses a major
challenge to LBs. Usually, enriched CTCs are identified
using specific tumor-associated biomarkers at either
the protein or mRNA level. In patients with epithelial
tumors, the identification of epithelial markers can be
difficult due to their downregulation during the process of epithelial to mesenchymal transition (EMT),
which can lead to false-negative results [219]. In addition, usually, a high starting concentration of CTCs is
required for the downstream analysis of individual or
clusters of CTCs at the DNA, RNA, or protein level,
using micromanipulation or DEP-array technologies
[220]. Although whole-genome amplification (WGA)
can be employed to generate sufficient quantities of
DNA required for sequencing analysis, this technique
can induce bias by distorting the initial template during the amplification process, and therefore new WGAfree techniques are required to increase the reliability
of these assays [221]. The establishment of permanent
CTC cell lines or the development of xenograft models
can allow a deeper insight into the CTC-blood microenvironment interactions, but the low number of CTCs
in the blood and the heterogeneity of tumors make
the establishment of cell lines and xenograft models
extremely challenging [222, 223]. Moreover, the development of these models requires a great deal of time,
has lower efficacy rates and is not cost-effective, making them unsuitable for clinical investigation.
Another limitation is the low specificity of ctDNAs due
to the presence of cfDNAs from normal tissues, which
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can lead to false-positive or false-negative results [218].
Moreover, to avoid the increase of non-tumoral cfDNA,
additional pre-analytical steps are required for the analysis as the cfDNA released from normal cells acts as a
diluent for the small fraction of ctDNA and can lead to
an inaccurate sampling of cfDNA [224]. Optimized preanalytical steps such as double plasma centrifugation,
proper incubation time, ambient temperatures, and special blood collection tubes for cfDNA can reduce the
background of wild-type DNA and provide reliable testing results [225, 226].
Moreover, the establishment of non-coding RNA signatures in the blood is more challenging than other common biomarkers due to their low abundance in body
fluids, lack of suitable housekeeping non-coding RNA
reference analytes, and high intra-patient variability.
These limitations lead to a lack of consistency between
biomarkers identified in different studies [227]. Laboratories performing LB assays might also need an initial
histological examination by tissue biopsy to avoid overinterpretation of the diagnostic data.
Undoubtedly, LB is an efficient non-invasive diagnostic
method that can provide comprehensive tumor-molecular profiling and real-time information on therapeutic
cancer targets, but there is a need to develop novel techniques and standardized approaches to overcome the
limitations that hamper the implementation of LB into
translational and clinical practice.

Conclusion and future directions
The present literature supports the validity of LB as a
minimally invasive diagnostic tool for the early diagnosis and monitoring of therapeutic response, cancer
screening in high-risk populations, assessment of tumor
heterogeneity, and detection of novel cancer driver mutations. Like tissue biopsy, LB provides molecular tumor
information that can allow early detection of tumor
burden long before the conventional tests can. Also, LB
has great potential to monitor the intratumor heterogeneity, determine the clonal nature of driver events and
evolutionary processes in different early-stage cancers,
and also serve as a predictive marker for occult metastasis. Moreover, the molecular characterization of tumors
unraveled using LB can track disease evolution and prevent disease relapses. Despite the myriad benefits, the
clinical application of LB is hampered due to some of
its limitations, such as lack of specificity and sensitivity,
lack of diverse standardization and isolation procedures,
and elevated economic costs. Current technology only
provides knowledge of tumor activity and gene expression at a superficial level. There is a need to improve
technology that allows multi-organ cancer detection and
in-depth tumor analysis. Thus, addressing the challenges
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associated with the use of LB through advances in
research and technology can allow its optimal integration
in clinical settings, leading to a profound change in cancer research.
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